Healthcare
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Sales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on pcp4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 million up 10% on pcp2H FY26 sales AUD$2.5 million up 6% on pcp4Q FY26 sales AUD$1.6 million up 1% on pcp Canada FY26 sales AUD$0.2 million down 55% on pcp2H FY26 sales AUD$0.1 million up >1000% on pcp4Q FY26 sales up 376% on pcp USA FY26 sales AUD$1.8 million up 7% on pcpFY26 sales
About this update from Immuron Limited
MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Continued Travelan® Australian sales growth in FY26 ( +10% on pcp ) can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing; (2) same store growth as a result of increased promotion and past promotions driving new customers and return customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South East Asian travel. New Travelan packaging and creative was launched in Q4 which should positively impact sales moving forward. Sales in the U.S. increased on the back on number of marketing initiatives ( AUD: +7% on pcp; USD +13% on pcp ) including: (1) improved Travelan® store on Amazon.com; (2) local U.S. Travelan® Facebook and Instagram pages; (3) increased paid social, influencer and organic social media marketing. These growth factors were offset by the impact of the Australian dollar strengthening against the US dollar. During FY25 we had a Q1 pipeline fill into over a thousand Canada retail doors on the back of securing listings within key pharmacy and grocery retail groups. We previously reported that sales picked up on the back of consumer promotions in Q2 FY26 ( +191% on prior quarter ) and Q3 FY26 ( +82% on prior quarter ). We continue to build Travelan® brand awareness within Canada though our in-store educational programs, in-store promotions, and social media marketing resulting in Q4 FY26 sales up 427% on pcp .